Pluristem Therapeutics Inc.  

(Public, NASDAQ:PSTI)   Watch this stock  
Find more results for psti
+0.02 (1.32%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.51 - 1.53
52 week 0.71 - 2.45
Open 1.51
Vol / Avg. 0.00/168,583.00
Mkt cap 124.27M
P/E     -
Div/yield     -
EPS -0.29
Shares 80.16M
Beta 0.63
Inst. own 4%
Jun 10, 2016
Pluristem Therapeutics Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -6511.08%
Operating margin - -6666.75%
EBITD margin - -6003.17%
Return on average assets -54.50% -34.71%
Return on average equity -62.50% -41.04%
Employees 160 -
CDP Score - -


Building #5 #20, MATAM Advanced Technology Park
HAIFA, 31905
+972-74-7108600 (Phone)
+972-74-7108765 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular, orthopedic, pulmonary, hematological and women's health diseases. The Company is focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's placenta expanded (PLX) cells are intended to function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals that are generated by the patient's own body. PLX cells are grown using its three-dimensional (3D), micro environment technology, which produces a product that requires no tissue matching prior to administration. Its PLX products are in clinical-stage development for multiple indications.

Officers and directors

Zalman Aberman Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Yaky Yanay CPA President, Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
Doron Shorrer CPA Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Moria Kwiat Director
Age: 36
Bio & Compensation  - Reuters
Hava Meretzki Director
Age: 46
Bio & Compensation  - Reuters
Israel Ben-Yoram Independent Director
Age: 55
Bio & Compensation  - Reuters
Issac Braun Independent Director
Age: 63
Bio & Compensation  - Reuters